--- title: 'Industry Daily Summary: What Happened on October 9, 2026' headline: Biohaven licenses IgG degraders to Ono for up to $100 million description: The deal covers three candidates in Asian markets. European biotechs also made several leadership changes. url: https://thebench.bio/news/industry/2026-10-09 topic: industry date: '2026-10-09' covers: - '2026-10-09' date_published: '2026-10-09T12:03:34Z' date_modified: '2026-10-09T12:03:34Z' sources: 2 publisher: The Bench (thebench.bio) --- # Industry Daily Summary: What Happened on October 9, 2026 **Biohaven licenses IgG degraders to Ono for up to $100 million** The deal covers three candidates in Asian markets. European biotechs also made several leadership changes. ## Today in brief Ono Pharmaceutical secured regional rights to three Biohaven drug candidates, with $80 million due at closing and a $20 million milestone payment expected within 12 months. [1] In Europe, Alligator Bioscience named a new CEO, while RQ Bio added a chief medical officer after raising $115 million. [2] ## Ono gets regional rights to Biohaven’s IgG degraders Biohaven gave Ono Pharmaceutical exclusive development and commercialization rights to BHV-1300, BHV-1310 and BHV-1320 in Japan, South Korea, Taiwan and ASEAN countries. [1] Ono will pay $80 million at closing, followed by a $20 million milestone payment expected within 12 months. [1] Biohaven may also earn royalties of about 20% on sales in those markets, while retaining rights in the United States, Europe, China and other territories. [1] The candidates target autoimmune diseases driven by immunoglobulin G (IgG), an antibody involved in immune responses. [1] BHV-1300 is in a pivotal Phase 3 study for Graves’ disease. Ongoing Phase 1 testing found that subcutaneous dosing reduced total IgG by as much as 87% while sparing the IgG3 subtype. [1] The agreement also covers the follow-on candidates BHV-1310 and BHV-1320. [1] ## European biotechs change leadership Alligator Bioscience finance chief Johan Giléus is due to replace CEO Søren Bregenholt on January 1, 2027, while keeping the finance role. [2] The company plans to operate with minimal staff after ending internal development of mitazalimab and shifting its focus to its financial interest in HLX22. [2] After raising $115 million in a Series A round, RQ Bio appointed Gavin Koh as chief medical officer and hired staff in manufacturing, clinical operations and program management. [2] The financing is intended to advance RQB01, an influenza antibody in studies required before clinical testing. [2] Sensorion named Louis Arcudi chief financial officer on October 7. The company expects to begin clinical testing of SENS-601 by early 2027. [2] Sensorion filed confidentially for a possible U.S. listing in September. [2] ## Also worth knowing - Hans Preusting became Mendus’s chief operating officer on October 5 and left its board. Spica Therapeutics named Jeff Abbey CEO on October 6, and Constructive Bio appointed Feroze Ujjainwalla chief commercial officer on October 8. [2] ## The day in numbers - **$80 million**: Ono’s payment to Biohaven at closing under the licensing agreement. [1] - **$20 million**: Additional milestone payment expected within 12 months. [1] - **About 20%**: Royalties Biohaven may earn on sales in Ono’s licensed territories. [1] - **87%**: Largest reported reduction in total IgG in ongoing Phase 1 testing of BHV-1300. [1] - **$115 million**: RQ Bio’s Series A financing to advance its influenza antibody RQB01 toward clinical testing. [2] ## Also published - [Saudi Arabia’s biotech momentum: inside RGMBS 2026](), Labiotech - [Your Weekly TechBio News 🟩](), MetaphysicalCells ## Sources 1. [Biohaven partners with Ono in $100m IgG degrader deal](), Pharmaceutical Technology, 2026-10-09 2. [Alligator’s CFO takes the top job, Sensorion names finance chief and RQ Bio appoints new CMO](), European Biotechnology, 2026-10-09 --- The Bench wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: